SOURCE: NeuroInvestment

NeuroInvestment

February 03, 2011 06:00 ET

Migraine Therapeutics Reviewed by NeuroInvestment

CARDIFF, CA--(Marketwire - February 3, 2011) - NI Research has released the February issue of NeuroInvestment, which reviews the status and prospects of migraine therapeutics. The triptans have been successful, but far from perfect in terms of rapidity and duration of effect, and their cardiovascular side effect profile. The class will all, with but one minor exception, go generic by 2013. In the face of this commercial transformation, the next generation of migraine therapeutics involves two main categories: Alternative delivery methods and novel mechanisms of action.

Among the companies which have developed alternative delivery methods are NuPathe (Zelrix), MAP (Levadex), and Zogenix (Sumavel). Drugs utilizing non-triptan mechanisms that are reviewed include NOS inhibitors from NeurAxon; CGRP-antagonists from Merck and Boehringer-Ingelheim; the buffered diclofenac reformulation from Nautilus; and a 5HT-1f drug from CoLucid.

The February issue of NeuroInvestment also evaluates the data from Targacept's (NASDAQ: TRGT) trial of TC-5619 for schizophrenia; reports what was observed at JP Morgan regarding early evidence for a return of interest in CNS; and includes a review of NuPathe, a company developing alternate delivery reformulations of established drugs for migraine, Parkinson's, and schizophrenia.

About NeuroInvestment: NeuroInvestment is the independent, monthly review of the neurotherapeutics area. A one-year subscription is $2100, email or hardcopy. Add $250 for dual delivery, add $50 for airmail delivery outside North America. A three-month trial subscription is US$700. The migraine issue is available as a single-issue purchase for $350.

A recent sample issue of NeuroInvestment is available for download at: http://www.neuroinvestment.com/NewPublications.html.

NI Research is the leading publisher of independent research on the neuropharmaceutical/therapeutic industry. NI Research has published NeuroInvestment since 1995; the Private CNS Company Review since 2003; and CNS Disorders/Therapeutics, an annual compendium of all neuro-oriented R&D programs, since 2007.

NI Research has developed an unmatched information base regarding both publicly and privately held neuro-oriented companies, and offers M&A/licensing consultation and research for large and small pharmaceutical firms.

Contact Information